Clinical Trial Update: Validation of the O3 Regional Somatic Tissue Oxygenation Monitor [NA]

View source ↗

Summary

A completed clinical trial evaluating the O3 Regional Somatic Tissue Oxygenation Monitor by Masimo Corporation; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oxygen Deficiency

Drugs mentioned

• O3 Regional Somatic Tissue Oxygenation Monitor (NA)

Snippet

Sponsor: Masimo Corporation | Conditions: Oxygen Deficiency | NA | Status: COMPLETED | Results posted: 2022-06-27